3 Life Sciences Commercialisation Company, IT Services Company and Defence Microwave Systems Maker Stocks With a Strong Future Roadmap: Indegene, Coforge and Astra Microwave Products

Pharma tech, IT and defence radio stocks bring together companies with a visible plan for the years ahead. Indegene, Coforge and Astra Microwave Products cover a life sciences commercialisation company, an IT services company and a defence microwave systems maker.

This list covers three pharma tech, IT and defence radio stocks with complete current figures: Indegene, Coforge and Astra Microwave Products. Every figure comes from the latest reported financials and the 10 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma Tech, IT and Defence Radio Stocks?

Pharma tech, IT and defence radio stocks are listed companies that help drug and medical device firms plan, launch and sell products using technology, provide software and digital engineering services to global clients, and build radio frequency and microwave systems for defence and space. Their earnings depend on pharma outsourcing, client technology budgets and defence orders.

Pharma Tech, IT and Defence Radio Stocks at a Glance

On valuation, Indegene trades at a P/E below the industry P/E, while Coforge and Astra Microwave Products trade above it, which reflects the growth the market already expects. Readers comparing pharma tech, IT and defence radio stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma Tech, IT and Defence Radio Stocks Have a Strong Roadmap in India?

Pharma tech, IT and defence radio stocks have a strong roadmap in India because rising outsourcing by life science firms, wider enterprise adoption of digital services and strong defence indigenisation keep widening the market for these companies.

• Life science services. Drug makers outsource launch and data work.
• IT services. Enterprises keep modernising their systems.
• Defence radio systems. Armed forces need home built sensors.

Why Indegene Features Among These Pharma Tech, IT and Defence Radio Stocks

Among the pharma tech, IT and defence radio stocks on this list, Indegene is a Bengaluru-based healthcare technology and services company that helps biopharma and medical technology firms with commercial, medical and regulatory work using data and technology.

The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2.

Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore.

Roadmap: The company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.

What to watch: Monitor client additions, platform adoption and growth in artificial intelligence services.

Why Coforge Features Among These Pharma Tech, IT and Defence Radio Stocks

Among the pharma technology, digital services and radar shares on this list, Coforge is a global IT services company that offers digital engineering, cloud, data and application services to clients in travel, banking, insurance and other industries.

Revenue rose from Rs 6,484 crore in FY22 to Rs 16,476 crore in FY26, a compound annual growth rate of 26.3%. Net profit grew from Rs 715 crore in FY22 to Rs 1,674 crore in FY26, which works out to a compound annual growth rate of 23.7%.

In the June 2026 quarter, revenue grew 49.2% year on year to Rs 5,554 crore, while net profit rose 49.2% to Rs 532 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 85,024 crore. The stock trades at a P/E of 44.3, above the industry P/E of 17.5.

Roadmap: The company focuses on large, long-running deals in sectors where it has deep domain strength. A rising share of cloud and data work and the acquisition of a leading digital services business have strengthened its pipeline.

What to watch: Check the order intake and the pace of large deal conversion.

Why Astra Microwave Products Features Among These Pharma Tech, IT and Defence Radio Stocks

Among the three companies on this list, Astra Microwave Products is a Hyderabad-based maker of microwave and radio frequency components, sub-systems and systems used in radars, missiles, electronic warfare and satellite communication.

Revenue rose from Rs 757 crore in FY22 to Rs 1,181 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 37.9 crore in FY22 to Rs 193 crore in FY26, which works out to a compound annual growth rate of 50.2%.

The company has a return on equity of 14.7%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 15,358 crore. The stock trades at a P/E of 81.2, above the industry P/E of 48.1.

Roadmap: The company supplies sub-systems to major defence and space programmes and is moving up from components to complete systems. Its design strength in radio frequency and microwave electronics suits the shift to indigenous radars and missile programmes.

What to watch: Check the timing of large order execution, since quarterly revenue in defence electronics can move with delivery schedules.

Indegene vs Coforge vs Astra Microwave Products on Key Financials

The table below sets the three pharma tech, IT and defence radio stocks side by side on revenue, profit and margin, using reported figures.

Coforge posts the highest return on equity in this group at 16.3%. Coforge combines the largest FY26 revenue at Rs 16,476 crore with the fastest revenue growth, a 26.3% compound annual rate. A useful habit with pharma tech, IT and defence radio stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pharma Tech, IT and Defence Radio Stocks

Every theme carries risks that deserve a check before any decision. For these pharma tech, IT and defence radio stocks, the main points are: Long-term pharma technology, digital services and radar shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Client spending. Technology budgets can vary with global conditions.
• Client spending. Technology budgets can vary with global conditions.
• Order timing. Defence and space orders can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma tech, IT and defence radio stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma Tech, IT and Defence Radio Stocks

Pharma tech, IT and defence radio stocks suit investors who prefer to study business strength before price moves. Indegene, Coforge and Astra Microwave Products each have a clear plan to grow. Based on the 10 November 2026 close, Indegene trades at Rs 614.6, Coforge at Rs 2,047 and Astra Microwave Products at Rs 1,659.7. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these pharma tech, IT and defence radio stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track pharma tech, IT and defence radio stocks, set price alerts and get research-backed stock ideas.

What are pharma tech, IT and defence radio stocks?

Ans. Pharma tech, IT and defence radio stocks are listed companies that help drug and medical device firms plan, launch and sell products using technology, provide software and digital engineering services to global clients, and build radio frequency and microwave systems for defence and space. Their earnings depend on pharma outsourcing, client technology budgets and defence orders. This list looks at three of them, Indegene, Coforge and Astra Microwave Products, using reported FY22 to FY26 financials and the 10 November 2026 closing prices.

Which pharma tech, IT and defence radio stocks are covered in this list?

Ans. This list covers Indegene, Coforge and Astra Microwave Products. Based on the 10 November 2026 close, Indegene traded at Rs 614.6, Coforge at Rs 2,047 and Astra Microwave Products at Rs 1,659.7. Their return on equity ranges from 12.8% to 16.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 26.3%.

Why do pharma tech, IT and defence radio stocks have a strong future roadmap in India?

Ans. Pharma tech, IT and defence radio stocks have a strong roadmap in India because rising outsourcing by life science firms, wider enterprise adoption of digital services and strong defence indigenisation keep widening the market for these companies. The main drivers are as follows. Life science services. Drug makers outsource launch and data work. IT services. Enterprises keep modernising their systems. Defence radio systems. Armed forces need home built sensors. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Indegene performed financially?

Ans. Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2. Looking ahead, the company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.

How has Coforge performed financially?

Ans. Revenue rose from Rs 6,484 crore in FY22 to Rs 16,476 crore in FY26, a compound annual growth rate of 26.3%. Net profit grew from Rs 715 crore in FY22 to Rs 1,674 crore in FY26, which works out to a compound annual growth rate of 23.7%. In the June 2026 quarter, revenue grew 49.2% year on year to Rs 5,554 crore, while net profit rose 49.2% to Rs 532 crore. The company has a return on equity of 16.3%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 85,024 crore. The stock trades at a P/E of 44.3, above the industry P/E of 17.5. Looking ahead, the company focuses on large, long-running deals in sectors where it has deep domain strength. A rising share of cloud and data work and the acquisition of a leading digital services business have strengthened its pipeline.

How has Astra Microwave Products performed financially?

Ans. Revenue rose from Rs 757 crore in FY22 to Rs 1,181 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 37.9 crore in FY22 to Rs 193 crore in FY26, which works out to a compound annual growth rate of 50.2%. The company has a return on equity of 14.7%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 15,358 crore. The stock trades at a P/E of 81.2, above the industry P/E of 48.1. Looking ahead, the company supplies sub-systems to major defence and space programmes and is moving up from components to complete systems. Its design strength in radio frequency and microwave electronics suits the shift to indigenous radars and missile programmes.

What risks should investors check before buying pharma tech, IT and defence radio stocks?

Ans. Investors should check a few risks before buying pharma tech, IT and defence radio stocks. Client spending. Technology budgets can vary with global conditions. Client spending. Technology budgets can vary with global conditions. Order timing. Defence and space orders can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma tech, IT and defence radio stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 10 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.